Boehringer Ingelheim Venture Fund

Operating as a separate legal entity, the Boehringer Ingelheim Corporate Venture Fund drives innovation through its strategic investments in early-stage science and technology. With an investment volume of 250 million euro, the Venture Fund invests in biotech and start-up companies with innovative concepts and technologies that have the potential to provide ground-breaking therapeutic platforms. The Venture Fund also creates companies when it identifies promising research projects in university and academia.

The Venture Fund’s interest in young, mainly technology-oriented companies demonstrates its commitment to investigate new ideas and new science to prepare the way for Boehringer Ingelheim to expand into new therapeutic approaches and businesses.